The activity of gentamicin at various concentrations against two strains of Enterococcus faecalis was investigated in vitro and in a rabbit model of aortic endocarditis. In vitro, gentamicin at 0.5 to 4 times the MIC failed to reduce the number of bacteria at 24 h. Rabbit or human serum dramatically increased gentamicin activity, leading to a >3-log 10 CFU/ml decrease in bacterial counts when the drug concentration exceeded the MIC. Susceptibility testing in the presence of serum was predictive of in vivo activity, since gentamicin alone significantly reduced the number of surviving bacteria in the vegetations if the peak-to-MIC ratio was greater than 1. However, gentamicin selected resistant mutants in rabbits. The intrinsic activity of gentamicin should be taken into account in evaluation of combinations of gentamicin and cell wall-active agents against enterococci.Enterococci are intrinsically resistant to low levels of aminoglycosides due to inefficient active transport across the cytoplasmic membrane (13). Thus, aminoglycosides alone are considered inactive in the treatment of enterococcal infections and are usually combined with inhibitors of cell wall synthesis which may facilitate their uptake (16). Therapeutic regimens with once-daily doses achieving high peak levels of aminoglycosides in serum have been recommended since they provide increased activity, in comparison to more traditional administration of the drugs (1, 3, 4). Consistent with this notion, it was shown that the bactericidal activity of aminoglycosides is concentration dependent (6) and that high peak-to-MIC ratios could reduce the emergence of resistant mutants (5). We conducted the present study to determine if the higher peak levels of gentamicin in serum obtained with these new regimens affect the antienterococcal activity of the drug.
MATERIALS AND METHODSBacterial strains and media. Enterococcus faecalis JH2-2 is susceptible to glycopeptides and -lactams and is intrinsically resistant to low levels of aminoglycosides (12). E. faecalis BM4281 is a JH2-2 transconjugant harboring a 250-kb chromosomal genetic element conferring VanB-type resistance (21). BM4281 is significantly less resistant to gentamicin (MIC ϭ 5 g/ml) than JH2-2 (MIC ϭ 16 g/ml) (14).In vitro susceptibility testing. The MICs of gentamicin (Unilabo, Levallois Perret, France) were determined by the method of Steers et al. (23) with 10 5 CFU per spot on brain heart infusion (BHI) agar (Difco Laboratories, Detroit, Mich.) after 24 h of incubation. For time-kill curves, exponentially growing E. faecalis was diluted in glass tubes containing 10 ml of BHI broth (pH 7.0; Difco) or 5 ml of BHI broth and 5 ml of undiluted complement-intact rabbit serum (mixture pH 7.4; Sigma Chemical Co., St. Louis, Mo.) or 5 ml of BHI broth and 5 ml of undiluted complement-intact human serum (mixture pH 7.4; Sigma) to obtain 10 7 CFU/ml and was incubated with gentamicin at various concentrations (0.5 to 4 times the MIC). Aliquots were taken after 0, 3, 6, and 24 h of incubation and plated on B...